PP-XXX-GBR-XXXX. XXXX 2025

This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.

Home

Menu

Close

Unmet NeedEfficacyEfficacy Home PageTrial DesignClinical RemissionEndoscopic ImprovementCorticosteroid-Free RemissionIsolated ProctitisBio/JAKi Subgroups DataInduction RespondersSymptomatic ResponseBowel UrgencySafetyAdverse eventsPooled and Interim Safety DataSpecial Warnings and PrecautionsCardiac and Ocular Adverse ReactionsGetting StartedGetting StartedContraindications and Interactions

Pre-first Dose Testing
ResourcesEventsMaterialsVideos

VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.1

Deliver on your patients' preference for oral treatment

The era of oral advanced treatments* in ulcerative colitis (UC) is here

The treatment landscape for UC in the UK is changing:

  • Multiple oral advanced treatments* in UC have been approved since 20181–23 

  • The NHS has committed through its Long-Term Plan to administering appropriate therapy 'closer to home' to provide treatment options for patient which may reduce the operational and financial burden on hospitals and healthcare providers24

*Advanced treatments in UC are defined as biologics, S1P receptor modulators and JAK inhibitors.25
 

Quick links card

Physicians now have the option to prescribe oral treatments, that aligns with the NHS Long Term Plan of 'closer to home' care, across many lies of advanced UC therapy1–24
 

Discover the possibilites on the route where clinicial goals and patient preferences can converge

It is believed that therapy options should be as convenient as possible for patients with UC, as this is a disease with a high symptom burden, which impacts patients' freedom and independence26–34

The availability of multiple oral advanced therapies* provides physicians with the treatment options to meet their patients' preferences.4–24,26–28

*Advanced treatments in UC are defined as biologics, S1P receptor modulators and JAK inhibitors.25

 

What are patients saying?
Evidence shows that the majoriy of patients with UC prefer oral therapy32–34
In a Spanish nationwide survey, nearly 80% of patients (n=585) believed that UC prevents them leading a normal life.32
Header 2

Second Accordion Content

Header 1

First Accordion Content

Header 2

Second Accordion Content

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-11245. January 2025
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​